Skip to main content
SpringerLink
Log in

The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model

  • Brief communication
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The development of endometrial cancer is a potential risk during long-term tamoxifen therapy for breast cancer. In order to protect the uterus, progestin treatment has been proposed for these patients. However, within the 7,12-dimethylbenzanthracene-induced rat mammary model, progesterone is known to reverse the antitumor effects of tamoxifen. This study shows that progesterone administered intermittently still reverses the antitumor effects of tamoxifen in this model. This effect of progesterone is not due to a decrease in the tissue levels of tamoxifen, and may be direct, via the progesterone receptor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrine Rev 11: 578–610, 1990

    Google Scholar 

  2. Gibson DFC, Jordan VC: Adjuvant antiestrogen therapy for breast cancer: past, present, and future. In: Cady B, Bland KI (eds) The Surgical Clinics of North America Vol 4. Breast Cancer: Strategies for the 1990's. WB Saunders Company, Philadelphia, 1990, p 1103–1113

    Google Scholar 

  3. EBCTCC: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319: 1681–1691, 1988

    Google Scholar 

  4. Falkson HC, Gray R, Wolberg WH, Gilchrist KW, Harris JE, Tormey DC, Falkson G: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group Phase III study. J Clin Oncol 8: 599–607, 1990

    Google Scholar 

  5. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleaven JF: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60: 126–131, 1989

    Google Scholar 

  6. News. Tamoxifen trial. J Natl Cancer Inst 83: 399, 1991

    Google Scholar 

  7. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E: Tamoxifen and the uterus and endometrium. Lancet 1: 375, 1989

    Google Scholar 

  8. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812–815, 1988

    Google Scholar 

  9. Fornander T, Rutqvist LE, Cedermark BV, Glas U, Mattson A, Silversward JD, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjolmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117–120, 1989

    Google Scholar 

  10. Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013–1017, 1991

    Google Scholar 

  11. Gusberg SB: Tamoxifen for breast cancer: associated endometrial cancer. Cancer 65: 1463–1464, 1990

    Google Scholar 

  12. Kimura J, Obata T, Okada H: Effects of clomiphene citrate and progesterone on resting and proliferative cell populations in mouse uterine epithelium. Endocrinol Japan 23: 401–406, 1976

    Google Scholar 

  13. Conti CJ, Gimenez-Conti IB, Conner EA, Lehmann JM, Gerschenson LE: Estrogen and progesterone regulation of proliferation, migration and loss in different target cells of rabbit uterine epithelium. Endocrinology 114: 345–351, 1984

    Google Scholar 

  14. Johnson PA, Muss H, Bonomi P, Von Roenn J, Wolter J, Paschold E, Black W, Cooper M: Megestrol acetate as primary hormonal therapy for breast cancer. Semin Oncol 15 (suppl 4): 34–37, 1988

    Google Scholar 

  15. Bergkvist L, Adami H, Persson I, Hoover R, Schairer C: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293–297, 1989

    Google Scholar 

  16. Huggins C, Yang NC: Induction and extinction of mammary cancer. Science 137: 257–262, 1962

    Google Scholar 

  17. Diamond JE, Hollander VP: Progesterone and breast cancer. Mt Sinai J Med 46: 225–235, 1979

    Google Scholar 

  18. Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83: 492–496, 1991

    Google Scholar 

  19. Hissom JR, Moore MR: Progestin effects on growth in the human breast cancer cell line T47D. Possible therapeutic implications. Biochem Biophys Res Commun 45: 706–711, 1987

    Google Scholar 

  20. Mouridsen HT, Elleman K, Mattsson W: Therapeutic effect of tamoxifen versus tamoxifen combined with medroxy progesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63: 171–175, 1979

    Google Scholar 

  21. Robinson SP, Jordan VC: Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 47: 5386–5390, 1987

    Google Scholar 

  22. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26: 883–888, 1990

    Google Scholar 

  23. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metabolism Disposition 19: 36–43, 1991

    Google Scholar 

  24. Jordan VC, Wolf ME, Mirecki DM, Whitford DA, Welschons WV: Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. CRC Crit Rev Clin Lab Sci 26: 97–152, 1988

    Google Scholar 

  25. Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Pasqualini CD: Hormone dependence of a mouse mammary tumor line inducedin vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 17: 33–43, 1990

    Google Scholar 

  26. Horwitz KB: Progestins inhibit growth and increase insulin receptors in antiestrogen-resistant T-47D human breast cancer cells; implications for endocrine therapies. Cancer Res 45: 167–173, 1985

    Google Scholar 

Download references

Author information

Author notes

  1. David FC Gibson

    Present address: Dermatology Department, Veterans Administration, Medical Center, 4150 Clement Street, 94121, San Francisco, CA, USA

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, 53792, Madison, WI, USA

    David FC Gibson, Delinda A. Johnson, Susan M. Langan-Fahey, Mary K. Lababidi, William H. Wolberg & V. Craig Jordan

Authors
  1. David FC Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Delinda A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan M. Langan-Fahey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary K. Lababidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William H. Wolberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibson, D.F., Johnson, D.A., Langan-Fahey, S.M. et al. The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model. Breast Cancer Res Tr 27, 283–287 (1993). https://doi.org/10.1007/BF00665699

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00665699

Key words

Search

Navigation